This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 11/19/2026 at 8:00 am EET
We reiterate our EUR 21.0 target price for Remedy, but following the share price drop, we update our recommendation to Buy (was Accumulate). Control Resonant has been successfully launched, and although the hit game option did not materialize, we estimate the game will be a commercially highly profitable project for Remedy. The successful launch of Resonant also reduces Remedy's short-term risks and, in our view, enables the self-publishing of future projects. Relative to this potential, we find the share valuation highly attractive.
In 2017, Remedy began its transition to a multi-project model and a journey up the value chain from a subcontractor to an independent game developer and publisher. Since then, much progress has been made, and the company now has the resources and capabilities to develop two projects simultaneously in full production. The company has also built the capabilities to self-publish its own games. As a result, the revenue and profit potential of games for Remedy is significantly higher than in previous game projects. Control Resonant, launched in September 2026, was Remedy's first self-published major single-player game. The game received good reviews (Metacritic 83), and players have received it even better than critics. The game sold over a million copies in about three weeks, making it the fastest-selling game in Remedy's history. Regarding future game releases, the company has Max Payne 1&2 Remake in full production under the subcontracting model, which we expect to be released in early 2027. In addition, the company has an as-yet-unnamed game project in the production readiness stage, which we expect to be Alan Wake 3.
Remedy guides for 2026 revenue and EBITDA to increase year-on-year. Based on our estimates (2026e revenue 99.7 MEUR, EBITDA 15.9 MEUR), the guidance is clearly beaten following the release of Control Resonant. However, as depreciation increases, EBIT will still remain slightly unprofitable. For 2027, we expect revenue to grow to 113 MEUR and EBITDA to rise to 23.2 MEUR. Growth is supported by the long tail of sales for Control Resonant. In addition, Remedy's share of the game's proceeds will increase once Annapurna's share of the production budget has been recouped. According to our estimates, royalties from Max Payne 1&2 Remake will begin in the second half of 2027. Of the company's 2027 targets, doubling revenue from the 2024 level is met in our estimates, but the EBITDA margin (2027e: 20.6%) falls short of the 30% target. In 2028, we expect EBITDA to rise to 32.3 MEUR (26.2% of revenue). This is driven by Max Payne royalties and the next self-published game, which we expect to be released at the end of the year. Exact visibility into game sales and royalties is weak, and the timing of game releases will continue to cause volatility in Remedy's figures for years to come.
The successful launch of Control Resonant has, in our view, reduced Remedy's risks, as the scenario of a failed launch is now off the table. We estimate that the game's cash flows, together with a strong balance sheet, will enable the financing and self-publishing of subsequent projects. On the other hand, the hit game option did not materialize, and the short-term element of surprise has been partly priced out of the share. However, based on our estimates for the coming years, the share valuation (2027e-2028e EV/EBITDA of 8x-6x) looks very low following the share price decline. The long-term potential is indicated in part by the base-case value of our DCF model (EUR 22.8). Over the next 12 months, we estimate that the share will be supported by the continuation of Resonant's sales and the likely launch of Max Payne Remake. In addition, further information on Remedy's subsequent game projects may be provided.